MRNS RSI Chart
Last 7 days
-84.4%
Last 30 days
-86.4%
Last 90 days
-86.6%
Trailing 12 Months
-82.7%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2023 | 21.7M | 26.0M | 31.0M | 31.0M |
2022 | 27.7M | 27.6M | 19.8M | 25.5M |
2021 | 3.6M | 5.4M | 15.4M | 15.3M |
2020 | 0 | 0 | 276.5K | 1.8M |
2016 | 72.0K | 91.0K | 112.0K | 127.5K |
2015 | 23.5K | 37.5K | 48.5K | 64.0K |
2014 | 38.6K | 30.3K | 21.9K | 13.5K |
2013 | 0 | 0 | 0 | 47.0K |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 27, 2024 | braunstein scott | acquired | 214,000 | 4.28 | 50,000 | chairman and ceo |
Feb 20, 2024 | shafer christina | sold | -20,582 | 9.56 | -2,153 | chief commercial officer |
Feb 20, 2024 | manning martha e | sold | -18,125 | 9.57 | -1,894 | svp, gen. counsel & corp. sec. |
Feb 16, 2024 | hulihan joseph | sold | -28,083 | 9.98 | -2,814 | chief medical officer |
Feb 16, 2024 | braunstein scott | sold | -117,789 | 9.94 | -11,850 | chairman and ceo |
Feb 16, 2024 | pfanstiel steven | sold | -30,827 | 9.97 | -3,092 | cfo and coo |
Jan 18, 2024 | manning martha e | acquired | - | - | 21,835 | svp, gen. counsel & corp. sec. |
Jan 18, 2024 | nochur sara | acquired | - | - | 4,600 | - |
Jan 18, 2024 | mayleben timothy m | acquired | - | - | 4,600 | - |
Jan 18, 2024 | ezickson elan | acquired | - | - | 4,600 | - |
Which funds bought or sold MRNS recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
Apr 12, 2024 | HARBOR INVESTMENT ADVISORY, LLC | unchanged | - | -68.00 | 334 | -% |
Apr 10, 2024 | SOA Wealth Advisors, LLC. | sold off | -100 | -435 | - | -% |
Apr 05, 2024 | GAMMA Investing LLC | added | 40.00 | 116 | 506 | -% |
Mar 22, 2024 | PNC FINANCIAL SERVICES GROUP, INC. | new | - | 76.00 | 76.00 | -% |
Mar 11, 2024 | VANGUARD GROUP INC | added | 3.72 | 8,309,350 | 29,058,000 | -% |
Mar 01, 2024 | GOLDMAN SACHS GROUP INC | added | 24.99 | 643,318 | 1,578,740 | -% |
Feb 28, 2024 | AMERICAN INTERNATIONAL GROUP, INC. | reduced | -0.4 | 70,268 | 273,989 | -% |
Feb 20, 2024 | EVENTIDE ASSET MANAGEMENT, LLC | unchanged | - | 12,774,600 | 49,241,100 | 0.80% |
Feb 16, 2024 | PRICE T ROWE ASSOCIATES INC /MD/ | added | 3.42 | 87,000 | 308,000 | -% |
Feb 15, 2024 | JANE STREET GROUP, LLC | reduced | -29.4 | -52,195 | 1,065,680 | -% |
Unveiling Marinus Pharmaceuticals Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Marinus Pharmaceuticals Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 39.7B | 6.8B | -8.42 | 5.79 | ||||
HILS | 22.4B | 152.6K | -2.4K | 146.8K | ||||
ALNY | 18.6B | 1.8B | -42.25 | 10.17 | ||||
BMRN | 17.3B | 2.4B | 103 | 7.14 | ||||
INCY | 12.0B | 3.7B | 20.07 | 3.25 | ||||
MID-CAP | ||||||||
APLS | 6.2B | 396.6M | -11.74 | 15.65 | ||||
BBIO | 4.5B | - | -6.94 | 60.35 | ||||
AXSM | 3.2B | 270.6M | -13.52 | 11.95 | ||||
ARWR | 3.0B | 240.7M | -10.03 | 12.36 | ||||
ACAD | 2.8B | 726.4M | -45.41 | 3.83 | ||||
SMALL-CAP | ||||||||
CPRX | 1.8B | 398.2M | 25.42 | 4.56 | ||||
NVAX | 576.6M | 983.7M | -1.06 | 0.59 | ||||
CRBP | 448.6M | 881.7K | -10.06 | 466.16 | ||||
INO | 256.8M | 4.9M | -1.9 | 52.78 | ||||
IBIO | 6.7M | 2.1M | -0.25 | 2.14 |
Marinus Pharmaceuticals Inc News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2016Q4 | 2016Q3 | 2016Q2 | 2016Q1 | 2015Q4 | 2015Q3 | 2015Q2 |
Revenue | -2.0% | 7,190,000 | 7,338,000 | 6,081,000 | 10,380,000 | 7,162,000 | 2,340,000 | 1,790,000 | 14,186,000 | 1,520,000 | 10,114,000 | 1,905,000 | 1,806,000 | 1,547,000 | 171,000 | 35,500 | 36,000 | 34,000 | 22,000 | 20,000 | 15,000 | 15,000 |
Costs and Expenses | 9.3% | 42,627,000 | 38,984,000 | 37,520,000 | 43,343,000 | 36,374,000 | 32,439,000 | 38,556,000 | 30,897,000 | 28,636,000 | 29,283,000 | 25,390,000 | 28,967,000 | - | - | - | - | - | - | - | - | - |
S&GA Expenses | 3.3% | 15,358,000 | 14,868,000 | 15,722,000 | 15,204,000 | 14,658,000 | 13,389,000 | 17,061,000 | 11,737,000 | 10,622,000 | 9,452,000 | 6,828,000 | 10,376,000 | 6,005,500 | 4,564,000 | - | - | - | - | - | - | - |
R&D Expenses | 11.5% | 26,382,000 | 23,661,000 | 21,412,000 | 27,933,000 | 21,424,000 | 19,002,000 | 21,495,000 | 17,991,000 | 18,014,000 | 18,353,000 | 18,562,000 | 18,591,000 | 13,044,000 | 11,306,000 | - | - | - | - | - | - | - |
EBITDA Margin | -1593.6% | -3.98 | -0.24 | -0.05 | -0.13 | -0.21 | -4.53 | -3.33 | -3.40 | -6.25 | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expenses | 1.3% | 4,298,000 | 4,242,000 | 4,208,000 | 4,147,000 | 3,690,000 | 2,634,000 | 2,656,000 | 1,692,000 | 1,553,000 | 678,000 | 351,000 | - | - | - | 98,500 | 118,000 | 124,000 | 124,000 | 121,500 | 121,000 | 117,000 |
Income Taxes | - | 38,000 | - | -1,538,000 | - | - | 1,752,000 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings Before Taxes | -26.7% | -41,769,000 | -32,972,000 | -33,472,000 | - | -32,675,000 | 75,042,000 | -39,433,000 | - | - | -19,507,000 | - | - | - | - | - | - | - | - | - | - | - |
EBT Margin | -484.6% | -4.55 | -0.78 | -0.63 | -0.76 | -0.64 | -4.98 | -3.58 | -3.56 | -6.44 | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income | -26.7% | -41,769,000 | -32,972,000 | -31,934,000 | -34,730,000 | -34,312,000 | 73,290,000 | -39,433,000 | -19,361,000 | -28,305,000 | -19,507,000 | -23,823,000 | -27,141,000 | -17,469,000 | -15,659,000 | - | - | - | - | - | - | - |
Net Income Margin | -5.5% | -4.56 | -4.33 | -1.07 | -1.62 | -0.78 | -0.70 | -3.86 | -3.28 | -6.44 | -5.72 | -15.49 | -21.25 | - | - | - | - | - | - | - | - | - |
Free Cashflow | -7.2% | -26,992,000 | -25,173,000 | -24,358,000 | -41,478,000 | -21,914,000 | -29,645,000 | -33,672,000 | -27,655,000 | -21,750,000 | 5,403,000 | -22,955,000 | -16,183,250 | -16,406,250 | -14,477,250 | - | - | - | - | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Assets | -14.9% | 171 | 201 | 201 | 227 | 260 | 185 | 109 | 141 | 137 | 159 | 125 | 134 | 150 | 100 | 113 | 85.00 | 99.00 | 46.00 | 59.00 | 68.00 | 75.00 |
Current Assets | -15.3% | 165 | 195 | 195 | 220 | 252 | 177 | 101 | 135 | 132 | 153 | 121 | 130 | 146 | 95.00 | 109 | 80.00 | 94.00 | 41.00 | 54.00 | 63.00 | 74.00 |
Cash Equivalents | -14.1% | 121 | 140 | 128 | 147 | 241 | 168 | 92.00 | 126 | 123 | 145 | 112 | 123 | 139 | 87.00 | 99.00 | 70.00 | 91.00 | 37.00 | 49.00 | 61.00 | 68.00 |
Inventory | -11.8% | 2.00 | 3.00 | 3.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net PPE | -1.7% | 4.00 | 4.00 | 4.00 | 4.00 | 4.00 | 6.00 | 6.00 | 3.00 | 2.00 | 3.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 |
Liabilities | 5.4% | 154 | 146 | 144 | 142 | 144 | 103 | 105 | 100 | 83.00 | 80.00 | 30.00 | 19.00 | 13.00 | 12.00 | 12.00 | 13.00 | 11.00 | 12.00 | 12.00 | 10.00 | 7.00 |
Current Liabilities | 33.0% | 41.00 | 31.00 | 26.00 | 22.00 | 25.00 | 21.00 | 23.00 | 20.00 | 41.00 | 38.00 | 17.00 | 16.00 | 11.00 | 9.00 | 10.00 | 10.00 | 8.00 | 9.00 | 9.00 | 7.00 | 7.00 |
Shareholder's Equity | -69.3% | 17.00 | 55.00 | 57.00 | 85.00 | 116 | 82.00 | 5.00 | 40.00 | 53.00 | 78.00 | 95.00 | 115 | 137 | 87.00 | 101 | 43.00 | 60.00 | 34.00 | 47.00 | 58.00 | 68.00 |
Retained Earnings | -7.9% | -571 | -530 | -497 | -465 | -430 | -396 | -469 | -430 | -410 | -382 | -362 | -339 | -311 | -294 | -278 | -263 | -235 | -220 | -206 | -193 | -181 |
Additional Paid-In Capital | 0.7% | 589 | 585 | 555 | 546 | 542 | 474 | 470 | 466 | 460 | 457 | 454 | 450 | 445 | 373 | 371 | 306 | 295 | 254 | 253 | 252 | 250 |
Shares Outstanding | 0.0% | 55.00 | 55.00 | 51.00 | 50.00 | 50.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | 37.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | - | - | - | 179 | - | - | - | 452 | - | - | - | 303 | - | - | - | 207 | - | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 |
Cashflow From Operations | -7.2% | -26,992 | -25,173 | -24,358 | -41,478 | -21,914 | -29,645 | -33,672 | -27,655 | -21,750 | 5,403 | -22,955 | -16,175 | -16,398 | -14,469 | -16,008 | -14,037 | -16,249 | -12,004 | -8,716 | -11,664 | -9,158 |
Share Based Compensation | -2.0% | 3,925 | 4,006 | 3,891 | 3,741 | 3,799 | 3,895 | 3,818 | 3,378 | 3,000 | 2,841 | 2,991 | 5,035 | 2,121 | 1,849 | 1,796 | 1,876 | 1,234 | 1,339 | 1,263 | 1,836 | 1,143 |
Cashflow From Investing | -45.8% | 6,466 | 11,920 | 5,004 | -51,995 | 79.00 | 106,114 | -335 | -86.00 | -721 | -872 | -864 | 1,042 | 2,482 | 2,982 | 495 | -6,697 | 1,964 | -255 | -2,696 | 4,868 | 14,923 |
Cashflow From Financing | -97.4% | 661 | 25,903 | 237 | -174 | 94,137 | -546 | 14.00 | 31,133 | 297 | 28,077 | 12,840 | 96.00 | 65,088 | -106 | 44,117 | 117 | 68,069 | -18.00 | - | -83.00 | 42,300 |
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 12 Months Ended | |
---|---|---|
Dec. 31, 2023 | Dec. 31, 2022 | |
Revenue: | ||
Federal contract revenue | $ 11,374 | $ 6,935 |
Total revenue | 30,989 | 25,478 |
Expenses: | ||
Research and development | 99,388 | 79,912 |
Selling, general and administrative | 61,152 | 56,845 |
Cost of IP license fee | 1,169 | |
Total expenses | 162,474 | 138,266 |
Loss from operations | (131,485) | (112,788) |
Interest income | 8,113 | 2,354 |
Interest expense | (16,895) | (10,672) |
(Loss) gain from sale of priority review voucher, net | (4,000) | 107,375 |
Other income (expense), net | 1,324 | (2,696) |
Loss before income taxes | (142,943) | (16,427) |
Benefit (provision) for income taxes | 1,538 | (3,389) |
Net loss applicable to common shareholders | $ (141,405) | $ (19,816) |
Per share information: | ||
Net loss per share of common stock-basic | $ (2.63) | $ (0.51) |
Net loss per share of common stock-diluted | $ (2.63) | $ (0.51) |
Basic weighted average shares outstanding | 53,746,518 | 39,072,599 |
Diluted weighted average shares outstanding | 53,746,518 | 39,072,599 |
Other comprehensive loss: | ||
Unrealized loss on available-for-sale securities | $ (20) | |
Total comprehensive loss | (141,425) | $ (19,816) |
Product revenue, net | ||
Revenue: | ||
Revenue | 19,561 | 2,872 |
Expenses: | ||
Cost of revenue | 1,909 | 190 |
Collaboration revenue | ||
Revenue: | ||
Revenue | 54 | 15,671 |
Expenses: | ||
Cost of revenue | $ 25 | $ 150 |
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2023 | Dec. 31, 2022 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 120,572 | $ 240,551 |
Short-term investments | 29,716 | |
Accounts receivable, net | 3,799 | 6,348 |
Inventory | 2,413 | 77 |
Prepaid expenses and other current assets | 8,746 | 5,402 |
Total current assets | 165,246 | 252,378 |
Property and equipment, net | 3,843 | 4,236 |
Other assets | 1,819 | 2,904 |
Total assets | 170,908 | 259,518 |
Current liabilities: | ||
Accounts payable | 4,003 | 4,461 |
Current portion of notes payable | 11,551 | |
Current portion of revenue interest financing payable | 2,211 | 1,020 |
Accrued expenses | 22,859 | 19,536 |
Total current liabilities | 40,624 | 25,017 |
Notes payable, net of deferred financing costs | 61,423 | 71,018 |
Revenue interest financing payable, net of deferred financing costs | 33,766 | 29,857 |
Contract liabilities, net | 17,545 | 16,285 |
Other long-term liabilities | 785 | 1,341 |
Total liabilities | 154,143 | 143,518 |
Stockholders' equity: | ||
Series A convertible preferred stock, $0.001 par value; 25,000,000 shares authorized, no shares issued and outstanding at December 31, 2023; 4,300 shares issued and outstanding at December 31, 2022 | 4,043 | |
Common stock, $0.001 par value; 150,000,000 shares authorized, 54,585,428 issued and 54,578,121 outstanding at December 31, 2023 and 49,650,074 issued and 49,642,767 outstanding at December 31, 2022 | 55 | 50 |
Additional paid-in capital | 588,656 | 542,428 |
Treasury stock at cost, 7,307 shares at December 31, 2023 and December 31, 2022 | ||
Accumulated other comprehensive loss | (20) | |
Accumulated deficit | (571,926) | (430,521) |
Total stockholders' equity | 16,765 | 116,000 |
Total liabilities and stockholders' equity | $ 170,908 | $ 259,518 |